Please login to the form below

Not currently logged in
Email:
Password:

BACE1 inhibitor

This page shows the latest BACE1 inhibitor news and features for those working in and with pharma, biotech and healthcare.

Another Alzheimer's bust as Merck & Co stops verubecestat study

Another Alzheimer's bust as Merck & Co stops verubecestat study

Another Alzheimer's bust as Merck &Co stops verubecestat study. Late-stage BACE1 failure could be an ominous signal for Eli Lilly/AZ and Biogen/Eisai. ... Merck &Co has abandoned the phase III trial of its BACE1 inhibitor verubecestat in Alzheimer’s in

Latest news

  • Alzheimer's disease pipeline takes multiple hits Alzheimer's disease pipeline takes multiple hits

    MK 8931 (Merck &Co.) is a potential first-in-class, potent Aß precursor protein cleaving enzyme (BACE1) inhibitor. ... LY 2886721 (Lilly) is another BACE1 inhibitor that was in phase I/II development in the US, Japan and some EU countries, but the phase

More from news
Approximately 1 fully matching, plus 1 partially matching documents found.

Latest Intelligence

  • Interview: Mike Hutton, Lilly Interview: Mike Hutton, Lilly

    Lilly has not been immune from such difficulties. Its BACE1 inhibitor LY 2886721 and amyloid-beta treatment semagacestat also failed, the latter in a large phase III clinical trial.

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Real Science Communications

Real Science Communications is a scientific centre of excellence, infusing credibility and scientific rigour into the conversations around health and...

Latest intelligence

No incentive for a cure
The paradox of ‘cost-effective but unaffordable’ life-saving medicines...
Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...

Infographics